To include your compound in the COVID-19 Resource Center, submit it here.

Virtual ICAAC

The Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), which had been scheduled for this week, was postponed until Dec. 16-19 in the aftermath of the World Trade Center attack. However, a look through the abstract catalog showed several areas to watch.

These include an FDA report on adverse events with two classes of antibiotics; revelations about the mechanism of action of Cubist Pharmaceuticals Inc.'s Daptomycin; anti-hepatitis B compounds from Bayer AG; and reports by Microcide Pharmaceuticals Inc. on the therapeutic leverage being seen with its efflux pump inhibitors.

Antibiotics and

Read the full 897 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers